Fc gamma receptor gene variants associated with rheumatoid arthritisNovember 10, 2005People with a specific combination of variants of two genes, encoding two different receptors for the antibody Fc gamma, are three times more likely to develop rheumatoid arthritis than individuals with different variant combinations. A study published today in the journal Arthritis Research & Therapy confirms previous findings of an association between the Fc gamma Receptor (FCGR) gene family and rheumatoid arthritis (RA). The study shows that a specific variant combination of two FCGR genes on chromosome one, a FCGR3A-FCGR3B haplotype, makes people more susceptible to RA. Ann Morgan, from the University of Leeds, and colleagues from other institutions in the UK studied the frequency of various FCGR haplotypes in a group of UK Caucasians (147 RA patients and 127 healthy individuals acting as controls). Dr Morgan is an Arthritis Research Campaign 'Clinician Scientist Fellow'. One specific FCGR3A-FCGR3B haplotype was found in 31% of RA patients and in 37% of RA patients with a more severe type of RA characterised by lumps around the joints, or nodules. Individuals with 2 copies of this haplotype (homozygous) are three times more likely to develop RA. Homozygous individuals who also have certain variants of human leukocyte antigen (HLA)-DRB1 alleles encoding the 'shared epitope' protein sequence (SE positive), a known risk factor for RA, have a 10 times higher risk of developing RA than SE negative individuals with other FCGR3 variants. The Fc gamma receptors play important roles in the initiation and regulation of many immunological and inflammatory processes. They also have the ability to bind RA-associated antibodies. This might explain their role in RA pathogenesis. BioMed Central |
|||||||||||||||||||||
| Related Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles Researchers find new way to attack inflammation in Graves' eye disease A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Pain thresholds linked to inflammation and sleep problems in arthritis patients Despite recent advances in anti-inflammatory therapy, many rheumatoid arthritis (RA) patients continue to suffer from pain. New therapy for vasculitis will help patients avoid infertility and cancer Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy. Strategy for mismatched stem cell transplants triggers protection against graft-vs.-host disease A new technique being tested in stem-cell transplants from imperfectly matched donors has revealed a striking, unforeseen response that can suppress graft-versus-host disease, a common and dangerous complication of mismatched transplants, report scientists from Dana-Farber Cancer Institute. Grains and lamb offer new sources of omega-3 CSIRO research on grains and lamb aimed at developing new dietary sources of long-chain omega-3 oils will be presented at the World Congress on Oils and Fats in Sydney this week. Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. Experimental approach may reverse rheumatoid arthritis and osteoporosis Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation. Promising new target emerges for autoimmune diseases University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. New 'biofactories' produce rare healing substances in the endangered Devil's claw plant Deep in Africa's Kalahari Desert lies the "Devil's claw," a plant that may hold the key to effective treatments for arthritis, tendonitis and other illnesses that affect millions each year. Abnormal Brain Circuits May Prevent Movement Disorder Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's. More Rheumatoid Arthritis Current Events and Rheumatoid Arthritis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||